Drug Profile
Sitaxentan - Pfizer
Alternative Names: IPI 1040; PF-1228305; Sitaxsentan; Sitaxsentan sodium; TBC 11251; ThelinLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Encysive Pharmaceuticals
- Developer Pfizer
- Class Antihypertensives; Benzodioxoles; Heart failure therapies; Isoxazoles; Small molecules; Sulfonamides; Thiophenes
- Mechanism of Action Endothelin A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Market Withdrawal Pulmonary arterial hypertension
- Discontinued Diastolic heart failure; Kidney disorders
Most Recent Events
- 10 Dec 2010 Discontinued - Phase-II for Kidney disorders in United Kingdom (PO)
- 10 Dec 2010 Discontinued - Phase-III for Pulmonary hypertension in Japan (PO)
- 10 Dec 2010 Discontinued - Phase-III for Pulmonary hypertension in USA (PO)